详情页 - 四川省肿瘤医院知识库

当前位置：首页 > 详情页

Discovery of novel polycyclic spiro-fused carbocyclicoxindole-based anticancer agents.

文献详情

资源类型：

作者：

机构： [a]State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University and Collaborative Innovation Center for Biotherapy, Chengdu 610041, China [b]Chengdu University, Sichuan Industrial Institute of Antibiotics, Chengdu 610052, China [c]Analytical & Testing Center, Sichuan University, Chengdu 610064, China [d]Department of Ophthalmology, West China Hospital, Sichuan University, Chengdu 610041, China

出处：

DOI：

ISSN：

关键词： Polycyclic spiro-fused carbocyclicoxindoles Antiproliferative activity p53 inducer MDM2

摘要：

A series of novel polycyclic spiro-fused carbocyclicoxindoles were synthesized and investigated for their in vitro antiproliferative activities against nine human cancer cell lines. Five compounds (10i, 10l, 10n, 10p, and 10r) demonstrated anticancer activities against A2780s cells with IC50 values of less than 30 μM. In particular, compound 10i showed anticancer activities against seven cancer cell lines and stronger activities than cisplatin in A2780s, A2780T, CT26, and HCT116 cells. Further studies illustrated that compound 10i arrested cell cycle in G1 phase and induced apoptosis of HCT116 cells. This compound also effectively increased the protein levels of cleaved caspase-3, p53, and MDM2. Molecular docking results revealed that compound 10i could bind well to the p53-binding site on MDM2, indicating that it might work by blocking the MDM2-p53 interactions. Copyright © 2016 Elsevier Masson SAS. All rights reserved.

基金：

语种：

WOS：

PubmedID：

中科院(CAS)分区：

出版当年[2017]版：

大类 | 2 区

化学

小类 | 1 区药物化学

最新[2023]版：

大类 | 2 区

医学

小类 | 1 区药物化学

第一作者：

第一作者机构： [a]State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University and Collaborative Innovation Center for Biotherapy, Chengdu 610041, China

共同第一作者：

通讯作者：

通讯机构： [a]State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University and Collaborative Innovation Center for Biotherapy, Chengdu 610041, China [b]Chengdu University, Sichuan Industrial Institute of Antibiotics, Chengdu 610052, China

推荐引用方式(GB/T 7714)：

APA：

MLA：

相关文献

[1]Long non-coding RNA XIST expedites lung adenocarcinoma progression through upregulating MDM2 expression via binding to miR-363-3p [2]P53、MDM2在鼻咽癌组织中的表达及其与鼻咽癌生物学行为、预后关系的分析研究 [3]Restoration of p53 using the novel MDM2-p53 antagonist APG115 suppresses dedifferentiated papillary thyroid cancer cells [4]Associations of MDM2 rs2279744 and TP53 rs1042522 polymorphisms with cervical cancer risk: A meta-analysis and systematic review [5]p53, MDM2, eIF4E and EGFR expression in nasopharyngeal carcinoma and their correlation with clinicopathological characteristics and prognosis: A retrospective study [6]Discovery of spirooxindole-derived small-molecule compounds as novel HDAC/MDM2 dual inhibitors and investigation of their anticancer activity [7]FAM3B promotes progression of oesophageal carcinoma via regulating the AKT-MDM2-p53 signalling axis and the epithelial-mesenchymal transition. [8]Studies on the Expression of P53, MDM2, eIF4e, and EGFR in Nasopharyngeal Carcinoma and its Correlation With the Nasopharyngeal Carcinoma Biological Behavior and Prognosis [9]Rational drug design, synthesis, and biological evaluation of novel chiral tetrahydronaphthalene-fused spirooxindole as MDM2-CDK4 dual inhibitor against glioblastoma. [10]Consistent Amplification of FRS2 and MDM2 in Low-grade Osteosarcoma A Genetic Study of 22 Cases With Clinicopathologic Analysis